Studies have reported that diosmetin decreases Bcl‐2 expression while increasing Bax and Bak expression in liver, lung, breast, gliomas, and colon cancers (Ma and Zhang 2020; Liu et al. 2016; Qiao et al. 2016). Here, BCL2 is linked to central nervous system cancer.